Trials / Completed
CompletedNCT05936281
A Study of the Efficacy of Genakumab in Prevention of Acute Flares in Gout Patients Initiating Urate-lowering TherapyUrate-lowering (GenSci048-202)
A Randomized, Open-lable, Multi-center, Active-controlled Phase 2 Study for Evaluating Efficacy and Safety of Genakumab in Prevention of Acute Flares in Gout Patients Initiating Urate-lowering TherapyUrate-lowering
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 165 (actual)
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the safety and efficacy of Genakumab in prevention of acute flares in gout patients initiating urate-lowering therapyurate-lowering
Detailed description
A randomized, open-lable, multi-center, active-controlled Phase 2 study. Patients are randomized to Genakumab 100mg single injection group, Genakumab 200mg single injection group or oral colchicine 0.5mg once a day.for 12 weeks group.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Genakumab for injection | 150 mg/1ml/ vial |
| DRUG | Colchicine | 0.5 mg/table |
Timeline
- Start date
- 2023-07-20
- Primary completion
- 2024-01-19
- Completion
- 2024-01-19
- First posted
- 2023-07-07
- Last updated
- 2025-01-01
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05936281. Inclusion in this directory is not an endorsement.